Top View
- Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances
- VIRGINIA MILITARY INSTITUTE Lexington, Virginia
- Obesity: Pathogenesis and Emerging Targets for Drug Development
- 022529Orig1s000
- List of Scheduling Actions, Controlled Substances And
- Legislative Bill 236
- Comparison of Methamphetamine and MDMA Extended Access Self-Administration
- FDA Briefing Document NDA 22529 Lorqess (Lorcaserin Hydrochloride)
- Minnesota Statutes 2020, Section 152.02
- Pharmacotherapy of Obesity: Available Medications and Drugs Under Investigation
- IRB Working Protocol Template
- Lorcaserin (Belviq) National Drug Monograph June 2013 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- 2018 Controlled Substance List
- Cardiovascular Risk and Obesity C
- Chapter 124 Controlled Substances
- Senate Substitute for HOUSE BILL No. 2262
- Introduced 13
- FDA Briefing Document NDA 22529 Lorcaserin Hydrochloride Tablets, 10 Mg Sponsor: Arena Pharmaceuticals Endocrinologic
- Lorcaserin As a Potential Opioid-Sparing Adjunct
- Lorcaserin Therapy for Severe Epilepsy of Childhood Onset a Case Series
- Lorcaserin (Belviq) for Weight Loss GABRIELLE JOHNSON, MD, and M
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- An Examination of the Mechanism of Action of Fenfluramine In
- Synthesis and Biological Evaluation of Disubstituted Pyrimidines As Selective 5-HT2C Agonists
- Department of Public Safety Report to the 2014 Legislature
- Examples of Medications with Effects on Serotonin
- 022529Orig1s000
- 10-01-20 Phone: 615-741-2650 Rule ID(S): 9404 Email: Publlcall Ons,Information@Tn .Gov File Date: 10/1/2020 Effective Date: 12/30/2020
- BELVIQ XR (Lorcaserin Hydrochloride) Extended-Release Tablets BELVIQ XR Treatment
- FDA Briefing Document Pharmacy Compounding Advisory Committee
- Senate Bill No.1017 (2021)
- December, 2020 (Revised) 1 RULES of TENNESSEE DEPARTMENT of MENTAL HEALTH and SUBSTANCE ABUSE SERVICES OFFICE of LICENSURE CHAPT
- Controlled Substances List (Adopted by Alabama State Board of Health on January 15, 2020, Effective January 15, 2020)
- Drugs of Abuse (2017 Edition)
- Emerging Selectivity of Serotonin Receptor Subtype–Targeted Drugs